Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine for Freezing of Gait in Parkinson's Disease
2024-516756-18-00Phase 3Authorised
- Sponsor
- Radboud University Medical Center
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in Parkinson's disease (PD) comparing Atomoxetine Aurobindo with Placebo (2 arms). Primary endpoint: Percentage of time frozen during FOG-provoking gait tasks in the dopaminergic OFF-state. Planned start Jun 2025; status: authorised.
02
Drugs
atomoxetine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2024-516756-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516756-18-00.